| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT02272686 Details | 2018-12-05 Interventional | 2 | 1 | Ibrutinib Lymphoma Lymphoma, B-Cel… | Slow Accrual - | |||
| NCT01188369 Details | 2018-12-03 Interventional | 4 | 20 | Simendan Hypertrophy Hypertrophy, Le… Diastolic Dysfu… Left Ventricula… | Terminated prematurely due to high incidence of postoperative atrial fibrillation. - | |||
| NCT01727843 Details | 2018-11-30 Interventional | 3 | 15 | Tranexamic Acid Femoral Neck Fr… Fractures, Bone Postoperative H… Femoral Neck Fr… | - - | |||
| NCT00657449 Details | 2018-11-30 Interventional | 4 | 45 | Rofecoxib Valdecoxib Acute Pain Ankle Injuries Sprains and Str… | See termination reason in detailed description. - | |||
| NCT00923247 NCT00863720 Details | 2018-11-29 Interventional | 1/2 | [1 Refs] | 22 | Bortezomib Thyroid Disease… Thyroid Neoplas… Medullary Thyro… | Terminated due to slow accrual,primary endpoint reached & investigator left NIH. - | ||
| NCT01293539 Details | 2018-11-27 Interventional | 2 | 10 | Melphalan Retinoblastoma | IAC is now recognized as part of standard of care treatment options in the US. - | |||
| NCT00621036 Details | 2018-11-26 Interventional | 2 | 0 | Antibodies Immunoglobulin … Immunoglobulins Immunoglobulins… Methotrexate Sargramostim Thiotepa Central Nervous… Intestinal Neop… Lymphoma Lymphoprolifera… Nervous System … Brain and Centr… Lymphoprolifera… Small Intestine… | MyVax did not meet its primary endpoints - | |||
| NCT03300362 Details | 2018-11-23 Interventional | 2 | 862 | Vaccines Influenza, Huma… Influenza | Change to recommended season flu vaccine in UK - | |||
| NCT00760318 Details | 2018-11-23 Interventional | 2 | 17 | Levetiracetam Dystonia Dystonic Disord… Torticollis Cervical Dyston… | Sponsor decided to stop enrollment to review data. - | |||
| NCT00412841 Details | 2018-11-23 Interventional | 2 | 43 | Atorvastatin Necrosis Osteonecrosis Avascular Necro… | - - | |||
| NCT03438344 Details | 2018-11-21 Interventional | 2 | 0 | Vaccines Leukemia Leukemia, Lymph… Leukemia, Myelo… Leukemia, Myelo… Leukemia, Myelo… Leukemia, Myelo… Lymphoma Myelodysplastic… Myeloproliferat… Precursor Cell … Accelerated Pha… Acute Lymphobla… Acute Myeloid L… Bone Marrow Tra… Chronic Lymphoc… Chronic Phase C… Hematopoietic C… Hodgkin Lymphom… Myelodysplastic… Myelofibrosis Myeloproliferat… Non-Hodgkin Lym… | PI Withdrawal - | |||
| NCT02044822 2013-003314-41 Details | 2018-11-19 Interventional | 2 | 102 | Idelalisib Rituximab Leukemia Leukemia, Lymph… Leukemia, Lymph… B-cell Chronic … | - Due to the early termination of the study, efficacy data were not available for all participants, and therefore the prespecified analyses were not conducted. | |||
| NCT01980888 2013-003313-17 Details | 2018-11-19 Interventional | 3 | 311 | Bendamustine Hy… Idelalisib Rituximab Leukemia Leukemia, Lymph… Leukemia, Lymph… Chronic Lymphoc… | - The study was terminated in agreement with the FDA due to urgent safety measures. Due to early study termination, the prespecified efficacy analyses were not conducted. The PFS data presented are investigator assessments rather than IRC assessments. | |||
| NCT01980875 2013-004551-20 Details | 2018-11-19 Interventional | 3 | 57 | Chlorambucil Idelalisib Obinutuzumab Leukemia Leukemia, Lymph… Leukemia, Lymph… Chronic Lymphoc… | - The study was terminated in agreement with the FDA due to urgent safety measures. Complete data were not collected for any participant. | |||
| NCT02334527 Details | 2018-11-16 Interventional | 2 | 12 | Palbociclib Carcinoma, Tran… Metastatic Urot… | Data from first 12 subjects-primary endpoint not met. Data analysis underway. - | |||
| NCT01853982 Details | 2018-11-16 Interventional | 3 | 4 | Ceftolozane Ceftolozane, ta… Piperacillin Piperacillin, T… Tazobactam Pneumonia Pneumonia, Vent… Ventilator-Asso… | Terminated to focus on a larger study within the clinical development program. This study was electively terminated to focus on a larger registrational study, which was also part of the clinical development program for nosocomial pneumonia. | |||
| NCT01732926 2012-004034-42 Details | 2018-11-16 Interventional | 3 | 475 | Bendamustine Hy… Idelalisib Rituximab Lymphoma Lymphoma, Non-H… Indolent Non-Ho… | - Due to the early termination of the study, efficacy data were not available for all participants, and therefore the prespecified analyses were not conducted. | |||
| NCT01732913 Details | 2018-11-16 Interventional | 3 | 295 | Idelalisib Rituximab Lymphoma Lymphoma, Non-H… Indolent Non-Ho… | - Due to the early termination of the study, efficacy data were not available for all participants, and therefore the prespecified analyses were not conducted. | |||
| NCT01203930 Details | 2018-11-16 Interventional | 2 | 105 | Idelalisib Rituximab Leukemia Leukemia, Lymph… Leukemia, Lymph… Lymphoma Chronic Lymphoc… Small Lymphocyt… | - - | |||
| NCT03693573 Details | 2018-11-15 Interventional | 3 | 0 | Atezolizumab Bevacizumab Carcinoma Carcinoma, Rena… Renal Cell Carc… | In the context of the ongoing evaluation of our data, we have determined that there is no need
to generate additional safety data at this time in the 1L mRCC pa - |